人类乳腺癌中的表皮生长因子受体：检测方法标准化的呼吁

Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology.

作者信息

Koenders P G, Faverly D, Beex L V, Bruggink E D, Kienhuis C B, Benraad T J

机构信息

Department of Experimental and Chemical Endocrinology, University Hospital Nijmegen, The Netherlands.

出版信息

Eur J Cancer. 1992;28(2-3):693-7. doi: 10.1016/s0959-8049(05)80128-5.

DOI:10.1016/s0959-8049(05)80128-5

PMID:1591096

Abstract

In a prospective study 200 primary human breast cancer specimens were analysed for epidermal growth factor receptor (EGFR) content by means of a multiple point ligand binding assay, proposed by the EORTC Receptor Study Group to be the standard EGFR assay. In 54% of the tumours the presence of saturable high affinity binding sites for epidermal growth factor could be demonstrated. The median EGFR level was 34 fmol/mg of membrane protein, the median Kd 0.50 nmd. Univariate analysis of the EGFR data stratified according to patient age, menopausal status, tumour size, axillary lymph node status, histological tumour type, tumour differentiation grade or the tumours' steroid hormone receptor status showed EGFR to be positively associated with younger age (P = 0.03), tumour dedifferentiation (P = 0.04) and steroid hormone receptor negativity (P less than 0.001). No association between EGFR and menopausal status, tumour size, axillary lymphnode status or histological tumour type could be demonstrated.

摘要

在一项前瞻性研究中，采用欧洲癌症研究与治疗组织（EORTC）受体研究组提议作为表皮生长因子受体（EGFR）标准检测方法的多点配体结合分析法，对200份原发性人类乳腺癌标本的EGFR含量进行了分析。在54%的肿瘤中，可证明存在对表皮生长因子的可饱和高亲和力结合位点。EGFR水平中位数为34 fmol/mg膜蛋白，解离常数（Kd）中位数为0.50 nmol/L。根据患者年龄、绝经状态、肿瘤大小、腋窝淋巴结状态、组织学肿瘤类型、肿瘤分化程度或肿瘤的类固醇激素受体状态对EGFR数据进行单因素分析，结果显示EGFR与较年轻年龄（P = 0.03）、肿瘤去分化（P = 0.04）和类固醇激素受体阴性（P < 0.001）呈正相关。未发现EGFR与绝经状态、肿瘤大小、腋窝淋巴结状态或组织学肿瘤类型之间存在关联。